Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs Simultaneous PCV13 and PPV23 in Elderly
NCT02637583Phase 4Completed
- Sponsor
- Universitätsklinikum Jena
- Start
- Oct 2017
- Primary completion
- Nov 2022
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal infection (3 arms), sponsored by Universitätsklinikum Jena. Primary endpoint: Immune response of B-memory cells. Started Oct 2017; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02637583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637583.